Li+

Ligand id: 5212

Name: Li+

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: lithium

References
1. Brown KM, Tracy DK. (2013)
Lithium: the pharmacodynamic actions of the amazing ion.
Ther Adv Psychopharmacol, 3 (3): 163-76. [PMID:24167688]
2. McAllister G, Whiting P, Hammond EA, Knowles MR, Atack JR, Bailey FJ, Maigetter R, Ragan CI. (1992)
cDNA cloning of human and rat brain myo-inositol monophosphatase. Expression and characterization of the human recombinant enzyme.
Biochem. J., 284 ( Pt 3): 749-54. [PMID:1377913]
3. Oruch R, Elderbi MA, Khattab HA, Pryme IF, Lund A. (2014)
Lithium: a review of pharmacology, clinical uses, and toxicity.
Eur. J. Pharmacol., 740: 464-73. [PMID:24991789]
4. Phiel CJ, Klein PS. (2001)
Molecular targets of lithium action.
Annu. Rev. Pharmacol. Toxicol., 41: 789-813. [PMID:11264477]
5. Ryves WJ, Dajani R, Pearl L, Harwood AJ. (2002)
Glycogen synthase kinase-3 inhibition by lithium and beryllium suggests the presence of two magnesium binding sites.
Biochem. Biophys. Res. Commun., 290 (3): 967-72. [PMID:11798168]
6. Ryves WJ, Harwood AJ. (2001)
Lithium inhibits glycogen synthase kinase-3 by competition for magnesium.
Biochem. Biophys. Res. Commun., 280 (3): 720-5. [PMID:11162580]